You are here

  • Home
  • Archive
  • Volume 6, Issue 6
  • Review: antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression

https://doi.org/10.1136/ebm.6.6.184

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ; Furukawa T, Streiner DL, Young LT.Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2000;(4):CD001026 (latest version 29 Aug 2000)..
    (2001) J Affect Disord 65, 173. Furukawa TA, Streiner DL, Young LT.. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study.. Jul;. :. –7.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In adults with major depression, does combination treatment with antidepressants and benzodiazepines lead to short term (< 8 wk) or long term (> 2 mo) symptomatic recovery or side effects?

    Data sources

    Studies were identified by searching Medline, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Biological Abstracts, LILACS, PsycLIT, the Cochrane Library, and the trial register of the Cochrane Depression, Anxiety, and Neurosis Group (January 1972 to December 1998); hand searching major mental health and general medicine journals; scanning thereference lists of identified articles; checking SciSearch; and making personal contacts.

    Study selection

    Studies were selected if they were randomised controlled trials comparing combined antidepressantbenzodiazepine treatment with antidepressants alone in adults with major depression. Studies were excluded if the antidepressant dose was < 100 mg of imipramine, or its equivalent daily, or the duration of the trial was < 4 weeks.

    Data extraction

    Data were extracted on patient …

    View Full Text

    Footnotes

    • Source of funding: Ministry of Health and Welfare, Japan and Uehara Memorial Foundation, Japan.

    • For correspondence: Professor T A Furukawa, Department of Psychiatry, Nagoya City University Medical School, Mizuho-cho Mizuho-ku, Nagoya 467-8601, Japan. Fax +8 52 852 0837.

    • Abstract and commentary also appear in Evidence-Based Mental Health.